Evidence Comparison
Compare Tesamorelin, CJC-1295, Ipamorelin side by side using the same BACToBasics evidence dataset that powers the interactive comparison tool. The table below focuses on mechanism, regulatory status, human evidence, safety context, anti-doping context, and primary sources.
Growth Hormone & Performance
FDA-approved
Regulatory-grade / large Phase 3
GHRH receptor agonist that stimulates endogenous growth hormone release and downstream IGF-1.
Unlike most GH-axis peptides sold online, tesamorelin has an FDA-approved product, a defined clinical indication, and regulatory-grade human evidence.
Open Tesamorelin guide →Growth Hormone & Performance
Not FDA-approved
Human pharmacology / early clinical
GHRH analog. The original studied CJC-1295 uses a Drug Affinity Complex to extend albumin binding and duration.
CJC-1295 has real human pharmacology data, but those data apply to the long-acting DAC compound and should not be generalized to online 'no DAC' products.
Open CJC-1295 guide →Growth Hormone & Performance
Not FDA-approved
Human pharmacology / early clinical
Ghrelin-receptor / growth-hormone-secretagogue receptor agonist that stimulates GH release.
There is direct human evidence that ipamorelin can stimulate GH release, but that is not the same as evidence for recreational performance or recovery benefits.
Open Ipamorelin guide →Save this comparison
Keep the current two- or three-compound comparison for quick access in My Tools.
Loading comparison tool...
Regulatory status and evidence level are separate ideas. A compound can have meaningful human research and still remain investigational, while an FDA-approved product can have approval only for specific indications and formulations.
BACToBasics also separates direct human intervention evidence from animal, cell, endogenous-biology, or related-molecule evidence so weaker evidence does not inherit the certainty of stronger research.
This page is generated from the same structured evidence records as the main interactive compare tool. Updating a compound's regulatory status, evidence summary, safety context, or source list updates both experiences rather than maintaining separate copies.
Read the Research & Editorial Policy →Evidence behind the comparison
These deep links are generated from the compounds in this comparison, so research and development pages stay connected as the underlying datasets grow.
Open the sourced public research and clinical-development timeline.
Open →
Research2 curated sources in the BACToBasics Research Library.
Open →
DevelopmentApproved · Approved.
Open →
UpdatesOpen the sourced public research and clinical-development timeline.
Open →
Research2 curated sources in the BACToBasics Research Library.
Open →
DevelopmentPhase 2 (historical) · Historical clinical development.
Open →
UpdatesOpen the sourced public research and clinical-development timeline.
Open →
Research2 curated sources in the BACToBasics Research Library.
Open →
Keep comparing
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
BACToBasics provides educational information only. Comparison pages are not medical advice, dosing advice, treatment guidance, anti-doping advice, or recommendations to use any compound.